Spasticity is one of the positive symptoms that characterized the Upper Motor Neuron (UMN) syndrome, which occurs in about 30% of post-stroke, in up to 85% of multiple sclerosis and in 71% of spinal cord injured patients. Nowadays, the most effective treatment consists in the pharmacological approach, which requires a precise evaluation of the patient’s condition to define the exact drug dose schedule. However, the current clinical scales adopted in the spasticity assessment do not satisfy the requirements in terms of precision and reliability, mostly because of inherent subjectivity and intra- and inter-rater variability. Therefore, to aid clinicians and improve the spasticity classification and evaluation, the development of a quantitative method for enhancing the quality of spasticity evaluation is mandatory.